VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 128 filers reported holding VERVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $94,345 | -29.3% | 7,115 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $133,406 | +94.1% | 7,115 | +49.3% | 0.00% | – |
| Q1 2023 | $68,726 | -25.5% | 4,766 | 0.0% | 0.00% | – |
| Q4 2022 | $92,222 | -41.6% | 4,766 | +3.3% | 0.00% | -100.0% |
| Q3 2022 | $158,000 | +251.1% | 4,612 | +58.0% | 0.00% | – |
| Q2 2022 | $45,000 | -32.8% | 2,919 | 0.0% | 0.00% | – |
| Q1 2022 | $67,000 | – | 2,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,508,809 | $57,251,000 | 8.18% |
| Alphabet Inc. | 10,974,011 | $250,427,000 | 8.12% |
| M28 Capital Management LP | 178,500 | $4,073,000 | 3.74% |
| Casdin Capital, LLC | 3,138,167 | $71,613,000 | 3.21% |
| Ally Bridge Group (NY) LLC | 105,360 | $2,404,000 | 1.78% |
| Redmile Group, LLC | 1,835,328 | $41,882,000 | 1.31% |
| Cormorant Asset Management, LP | 700,710 | $15,990,000 | 1.23% |
| Novo Holdings A/S | 750,000 | $17,115,000 | 0.90% |
| Artal Group S.A. | 400,000 | $9,128,000 | 0.38% |
| PFM Health Sciences, LP | 369,765 | $8,438,000 | 0.32% |